PE-7: Glepaglutide Pharmacokinetic Profile after Single Subcutaneous Injection in Human Subjects with Varying Degrees of Renal Function

Introduction: Glepaglutide (ZP1848, glepaglutide1-39, Zealand Pharma A/S) is a potent long acting GLP-2 analogue currently in phase-3 for the treatment of short bowel syndrome (SBS). Following subcutaneous injection of glepaglutide, 2 functionally active metabolites (M1: glepaglutide1-34 and M2: glepaglutide1-35) are formed from cleavages within the C-terminus. Patients with SBS are at risk of suffering from acute or chronic renal impairment,...